Du är nu på väg att lämna en GSK-hemsida

Denna länk leder till en hemsida som inte tillhör GSK. GSK tar inget ansvar för innehållet på tredje parts hemsidor.

Fortsätt

Tillbaka

  • ASYEVE0001=Event Registration-Portal
  • ASYEVE0002=Watched General Video
  • ASYEVE0003=Watched Virtual Rep Video
  • ASYEVE0004=Watched Patient Video
  • ASYEVE0005=Watched Expert Video
  • ASYEVE0006=Watched Webcast
  • ASYEVE0007=Downloaded Content-Portal
  • ASYEVE0008=Clicked to App Store
  • ASYEVE0009=Watched Learning Module Video
  • ASYEVE0010=eMail Sent
  • ASYEVE0011=eMail Read
  • ASYEVE0012=eMail Clicked
  • ASYEVE0013=Shared a Link
  • ASYEVE0014=Rep Request
  • ASYEVE0015=Joined health.gsk
  • ASYEVE0016=email Not Sent
  • ASYEVE0017=Email Not Sent
  • ASYEVE0018=Email Not Sent
  • ASYEVE0037=IJSFAID is not available
  • ASYEVE0038=EMAIL ID and IJSFAID is not available
  • ASYEVE0039=The user is opted out
  • ASYEVE0040=Scope IDs are different

Contact request

Stay informed

How to prescribe Triumeq?

Gå till Stäng Överst

Once-daily TRIUMEQ makes dosing and administration simple for your patients

TRIUMEQ (dolutegravir/abacavir/lamivudine) is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg. 1

Dosing recommendation 1

Triumeq dosing recommendation

Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient. Abacavir should not be used in patients known to carry the HLA-B*5701 allele. [1] Find out more on HLA-B*5701 screening here.

Convenient dosing 1,2

Convenient dosing of Triumeq

Contraindications 1

Hypersensitivity to dolutegravir, abacavir or lamivudine or to any of the excipients. Co-administration with dofetilide.

 

For further information, please see Triumeq prescribing information

▼This medicinal product is subject to additional monitoring.

*TRIUMEQ is a fixed-dose pill and should not be prescribed for patients requiring dose adjustments. Separate preparations of dolutegravir, abacavir, and lamivudine are available in cases where discontinuation or dose adjustment is required. 1
†TRIUMEQ is not recommended for patients with integrase inhibitor resistance.* 1
‡TRIUMEQ is not recommended for co-administration with efavirenz, nevirapine, rifampicin, or tipranavir/ritonavir. 1

*See How to prescribe Tivicay? for recommended dolutegravir dosing in patients with resistance to the integrase class.

References:

  1. TRIUMEQ (dolutegravir/abacavir/lamivudine) Summary of Product Characteristics, January 2017.
  2. Kandel CE, Walmsley S. Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug Design, Development and Therapy. 2015:9 3547-3555.

TRIUMEQ is a registered trademark of the ViiV Healthcare group of companies

Atripla is a registered trademark of Bristol-Myers Squibb & Gilead Sciences, LLC.